object(WP_Post)#4939 (24) {
["ID"]=>
int(14689)
["post_author"]=>
string(2) "22"
["post_date"]=>
string(19) "2025-10-29 20:04:06"
["post_date_gmt"]=>
string(19) "2025-10-29 19:04:06"
["post_content"]=>
string(4426) "
Across Europe and Switzerland, a new generation of biotech and med-tech pioneers is transforming the way we understand, predict, and treat disease. The convergence of AI, data science, and life sciences—from digital biomarkers and in-silico models to remote patient monitoring and digital twins—has created one of the fastest-growing investment frontiers. Yet these ventures require a form of capital that understands both science and scalability.
PrestaFlex provides Private Equity and structured financing tailored for this new era of digital medicine. Our role is to connect innovators developing AI-driven therapeutics, predictive biomarkers, and clinical-insight platforms with investors who recognize the long-term value of data-validated healthcare models.
We support companies working on:
- Digital biomarkers enabling early disease detection through connected devices and real-world signals.
- In-silico and AI/ML models accelerating clinical research and reducing R&D costs.
- Digital therapeutics that deliver measurable clinical outcomes through software.
- Omics-based analytics combining genomics, proteomics, and metabolomics for precision medicine.
- Remote patient monitoring and real-world data solutions improving adherence and outcomes.
- Medical Large Language Models (LLMs) that synthesize vast biomedical datasets into actionable intelligence.
- Digital twins of patients and organs, allowing simulation of treatment pathways before real-world intervention.
PrestaFlex structures equity, mezzanine, and hybrid instruments to fit each project’s maturity—bridging early-stage capital with institutional growth funding. Beyond financing, we analyze every business model using our five-pillar evaluation framework (solvency, liquidity, integrity, stability, reputation), ensuring investors access thoroughly vetted opportunities.
Our network of family offices, funds, and strategic partners seeks ventures that combine robust IP portfolios with scalable digital platforms. By focusing on CAPEX-to-OPEX transitions, recurring-revenue models, and regulatory readiness, we help founders build sustainable value instead of short-term speculation.
In an age where healthcare data are as valuable as gold, PrestaFlex acts as the bridge between capital and capability—empowering the companies shaping tomorrow’s medicine.
PrestaFlex — Your trusted partner for financing innovation in digital health, biotech & AI.
An article by Munur Aslan, Managing Director at PrestaFlex
See also our articles Corporate financing Zurich and Corporate financing Geneva for a broader perspective.
Across Europe and Switzerland, a new generation of biotech and med-tech pioneers is transforming the way we understand, predict, and treat disease. The convergence of AI, data science, and life sciences—from digital biomarkers and in-silico models to remote patient monitoring and digital twins—has created one of the fastest-growing investment frontiers. Yet these ventures require a form of capital that understands both science and scalability.
PrestaFlex provides Private Equity and structured financing tailored for this new era of digital medicine. Our role is to connect innovators developing AI-driven therapeutics, predictive biomarkers, and clinical-insight platforms with investors who recognize the long-term value of data-validated healthcare models.
We support companies working on:
- Digital biomarkers enabling early disease detection through connected devices and real-world signals.
- In-silico and AI/ML models accelerating clinical research and reducing R&D costs.
- Digital therapeutics that deliver measurable clinical outcomes through software.
- Omics-based analytics combining genomics, proteomics, and metabolomics for precision medicine.
- Remote patient monitoring and real-world data solutions improving adherence and outcomes.
- Medical Large Language Models (LLMs) that synthesize vast biomedical datasets into actionable intelligence.
- Digital twins of patients and organs, allowing simulation of treatment pathways before real-world intervention.
PrestaFlex structures equity, mezzanine, and hybrid instruments to fit each project’s maturity—bridging early-stage capital with institutional growth funding. Beyond financing, we analyze every business model using our five-pillar evaluation framework (solvency, liquidity, integrity, stability, reputation), ensuring investors access thoroughly vetted opportunities.
Our network of family offices, funds, and strategic partners seeks ventures that combine robust IP portfolios with scalable digital platforms. By focusing on CAPEX-to-OPEX transitions, recurring-revenue models, and regulatory readiness, we help founders build sustainable value instead of short-term speculation.
In an age where healthcare data are as valuable as gold, PrestaFlex acts as the bridge between capital and capability—empowering the companies shaping tomorrow’s medicine.
PrestaFlex — Your trusted partner for financing innovation in digital health, biotech & AI.
An article by Munur Aslan, Managing Director at PrestaFlex
See also our articles Corporate financing Zurich and Corporate financing Geneva for a broader perspective.
Alternative financing solutions for today's decision-makers and entrepreneurs